» Articles » PMID: 32800497

Management and Outcomes of Transvenous Pacing Leads in Patients Undergoing Transcatheter Tricuspid Valve Replacement

Overview
Publisher Elsevier
Date 2020 Aug 18
PMID 32800497
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The aim of this study was to determine the prevalence of pacemaker lead-related complications following transcatheter tricuspid valve replacement (TTVR).

Background: The rate of permanent pacemaker implantation following tricuspid valve (TV) surgery is high, and many patients have transvenous leads. The feasibility, safety, and outcomes of subsequently performing TTVR in the setting of transvenous pacemaker leads have not been established.

Methods: The VIVID (Valve-in-Valve International Database) registry was used to review 329 patients who underwent TTVR following TV repair or replacement. Patients were subdivided into 3 cohorts for intergroup comparisons: no lead, epicardial lead, and transvenous lead (entrapped or not entrapped during the TTVR procedure).

Results: Of 329 patients who underwent TTVR, 128 (39%) had prior pacing systems in place, 70 with epicardial and 58 with transvenous leads. A total of 31 patients had leads passing through the TV. Three patients had the right ventricular (RV) lead extracted prior to TTVR. The remaining 28 patients had the RV lead entrapped between the transcatheter TV implant and the surgical valve (n = 22) or the repaired TV (n = 6). One patient had displacement of the RV lead during the procedure, and 2 experienced lead failure during follow-up. Overall, there was no significant difference in the cumulative incidences of competing outcomes (death, TV reintervention, TV dysfunction) between patients with and those without pacing leads or entrapped RV leads.

Conclusions: TTVR in the setting of trans-TV pacemaker leads without lead extraction or re-replacement can be performed safely with a low risk for complications, offering an alternative to surgical TV replacement.

Citing Articles

Cardiac implantable electronic device carriers undergoing transcatheter tricuspid valve annuloplasty: real-world insights.

Wrobel J, Kirchner J, Friedrichs K, Gietzen T, Althoff J, Hasse C Clin Res Cardiol. 2025; .

PMID: 40063122 DOI: 10.1007/s00392-025-02616-5.


Outcomes of tricuspid transcatheter edge-to-edge repair in subjects with endocardial leads.

Goebel B, Lurz P, Schmitz T, Bekeredjian R, Nickenig G, Mollmann H EuroIntervention. 2025; 21(5):e253-e261.

PMID: 40028727 PMC: 11849534. DOI: 10.4244/EIJ-D-23-01033.


Successful implantation of an EVOQUE-tricuspid valve replacement system in a patient with two right ventricular implantable cardioverter-defibrillator leads: a case report.

Genske F, Marquetand C, Eitel I, Frerker C, Schmidt T Eur Heart J Case Rep. 2025; 9(2):ytaf066.

PMID: 40008265 PMC: 11851277. DOI: 10.1093/ehjcr/ytaf066.


Paravalvular positioning of a cardiac implantable electronic device electrode during tricuspid valve replacement.

Alpat S, Aydin A, Canpolat U, Yilmaz M Kardiochir Torakochirurgia Pol. 2025; 21(4):206-210.

PMID: 39781442 PMC: 11704753. DOI: 10.5114/kitp.2024.145836.


Transcatheter Tricuspid Valve Replacement: Case Selection, Technical Considerations, and Procedural Planning.

Shabbir M, Yadav P, Tiwari N, Velagapudi P US Cardiol. 2024; 17:e11.

PMID: 39559523 PMC: 11571394. DOI: 10.15420/usc.2023.07.